• BridgeBio Pharma published a medical research presentation on ATTRibute-CM subgroup results, reporting acoramidis slowed decline in Kansas City Cardiomyopathy Questionnaire Overall Summary Score versus placebo through month 30.
• Trial analysis showed least-squares mean difference of 9.9 points (95% CI 5.97-13.91; p<0.0001) in modified intention-to-treat population of 611 participants.
• Sensitivity analysis excluding any concomitant tafamidis use showed least-squares mean difference of 9.7 points (95% CI 5.26-14.13; p<0.0001) across 504 participants.
• Benefit was consistent across pre-specified subgroups, with no evidence of treatment-effect heterogeneity, though significance was not reached in eGFR below 45 mL/min/1.73 m² or NYHA class III subgroups due to small sample sizes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on May 09, 2026, and is solely responsible for the information contained therein.